Adamax Research Material丨What Is Known and What Must Be Batch-Verified

Adamax is described as a modified Semax-related research peptide.

The name alone does not tell us the exact chemical structure.

Short labels such as “adamantyl,” “AG,” or “adamantylated glycine” can refer to different end groups, linkers, or modified amino acids.

For this reason, the sequence, molecular formula, molecular weight, CAS number, salt form, purity, and solubility should come from the documents for the exact batch being tested.

Semax is better defined.

PubChem lists Semax as the seven-amino-acid peptide Met-Glu-His-Phe-Pro-Gly-Pro, with the sequence MEHFPGP, molecular formula C₃₇H₅₁N₉O₁₀S, average molecular weight 813.9 g/mol, exact mass 813.3479 Da, and CAS number 80714-61-0.^[1]

These Semax details should not be copied to Adamax unless the Adamax batch documents show the same feature.

What Semax Research Shows

Published Semax studies are useful background, but they are not direct evidence for Adamax.

In one rat experiment, Semax was linked with changes in BDNF protein (up to approximately 1.4-fold), TrkB tyrosine phosphorylation (approximately 1.6-fold), specific BDNF transcript levels (up to approximately 3-fold), and TrkB mRNA (approximately 2-fold) in the hippocampus.^[2]

Dolotov et al. (2006) found specific and reversible Semax binding in isolated basal-forebrain membrane preparations, with a dissociation constant (K_d) of 2.4 ± 1.0 nM and a B_max of 33.5 ± 7.9 fmol/mg protein; the binding required calcium ions.

In a separate in-vivo arm of the same study, intranasal Semax at 50 and 250 μg/kg was associated with increased BDNF protein in rat basal forebrain at 3 hours post-administration, but not in the cerebellum.^[3]

The study did not identify the binding site as MC4, MC5, an NMDA receptor, or another named receptor.

Adamax should therefore not be given a specific receptor pathway unless direct Adamax testing supports it.

Dmitrieva et al. (2010) studied Semax and Pro-Gly-Pro in a rat permanent middle cerebral artery occlusion (pMCAO) model of focal cerebral ischemia, reporting changes in the transcription of neurotrophins and their receptor genes in the cortex at 3, 24, and 72 hours post-occlusion.^[4]

This was a laboratory animal result.

It does not prove the same effect for Adamax and does not support a human-use claim.

Semax degradation and apparent persistence depend strongly on the biological matrix and experimental system.

One rat tracer study found rapid breakdown in biological samples, while a separate in-vitro study using isolated rat forebrain plasma membranes reported a degradation half-life longer than 1 hour in that specific setup; dipeptidylaminopeptidases were considered the main enzymes responsible, successively cleaving Semax to the HFPGP pentapeptide and the PGP tripeptide.^[5][6]

These results should not be used to assign Adamax a four-to-ten-hour half-life.

What Is Not Established for Adamax

Without a clear structure and direct test data, the following points should be listed as unknown rather than as facts:

• the exact amino-acid sequence and the point where the adamantane-related group is attached;
• the molecular formula, molecular weight, salt form, and CAS number;
• the half-life in buffer, cell media, plasma, or an animal model;
• blood-brain barrier transport or brain exposure;
• potency compared with Semax;
• BDNF or TrkB activity;
• MC4, MC5, NMDA, or other receptor activity;
• logP, water solubility, and solution stability.

Claims such as “two to three times more potent,” “four-to-ten-hour half-life,” “better blood-brain barrier penetration,” or “longer BDNF activation” should be removed unless they are supported by a direct Adamax study using a clearly identified test material.

What the Batch Documents Should Show

A useful Adamax specification should clearly state the full structure or sequence, all end modifications, any unusual amino acid or linker, the salt form, the theoretical molecular mass, and the batch number.

If a molecular weight such as 1,032 g/mol is reported, the document should also show the structure and formula used to calculate that number, and should specify whether it refers to the average molecular weight or the monoisotopic mass.

The identity result should include LC-MS, HRMS, or another suitable mass test.

The report should show the expected ion, the measured result, and enough method information to explain how the match was made.

A matching intact mass supports identity but may not distinguish positional isomers, sequence isomers, attachment sites, or stereochemistry.

Where these distinctions are material, MS/MS sequencing or another orthogonal structural method should be included.

HPLC purity is the area-normalized chromatographic purity of the main peak under the specified method and detector conditions.

It is useful for checking related impurities, but it does not by itself prove the peptide’s identity, actual peptide content, sterility, biological activity, or safety.

The report should include the HPLC method, detection wavelength, chromatogram, integration rules, and impurity results.

HPLC purity is also different from net peptide content.

Water, salt-form components, residual solvents, and other material can affect the amount weighed into an experiment.

Where relevant, the COA should report water or volatile content, residual solvents, salt-form content, and an assay or net peptide-content result.

Analytical methods should be suitable for their stated purpose.

ICH Q2(R2) addresses validation of analytical procedures, while ICH Q14 addresses analytical procedure development and lifecycle considerations.^[7]

COA limitation: A batch COA showing results within the supplier’s stated specifications is laboratory raw-material quality information only. It does not prove human-use safety, clinical effectiveness, veterinary suitability, or fitness for any non-research use.

Laboratory Handling

• Storage: Follow the batch-specific storage instruction. If the specification states −20°C, keep the lyophilized material dry and protected from light. Do not publish a shelf life unless it is supported by stability data.
• Solubility: Do a small test first with analytical-grade water or an assay-compatible laboratory buffer. Record the concentration, pH, appearance, and recovery. Do not call the material “water-soluble” without stating the tested concentration and conditions.
• Cosolvents: Use an organic cosolvent only when it is compatible with the assay. Keep the final cosolvent level the same in test and vehicle-control samples.
• Mixing: Use gentle mixing only. Avoid heating unless a stability test shows that heat does not increase oxidation, breakdown, or aggregation.
• Prepared solutions: Label each stock with the batch, solvent, concentration, preparation date, and storage condition. Set a use period from a stability assessment rather than guessing. In CGMP pharmaceutical laboratories, FDA guidance states that use periods for quantitative analytical solutions should be supported by formal stability studies; the same risk-based principle may be useful for research stocks, although the cited CGMP requirement does not automatically apply to every research-use-only laboratory.^[8]
• Freeze-thaw: When supported by the stability results, divide the solution into single-assay laboratory portions to reduce repeated freeze-thaw cycles.

Avoid human-injection preparation language, dosing syringes, and instructions that could reasonably be interpreted as a personal-use administration guide.

References to analytical syringes (e.g., Hamilton syringes, autosampler syringes) or syringe filters should be clearly identified as laboratory equipment.

Summary

The published sources in this article describe Semax, not Adamax.

The most accurate way to describe Adamax is as a batch-defined Semax-related research material whose exact structure and properties must be confirmed by its own analytical records.

In the absence of cited direct Adamax studies using a clearly characterized test material, the article should not claim a fixed molecular weight, a longer half-life, stronger potency, better brain exposure, or a specific receptor mechanism.

References

1. PubChem. ACTH (4-7), Pro-Gly-Pro- (Semax), CID 9811102. View source.
2. Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. PMID: 16996037. View source.
3. Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. 2006;97(Suppl 1):82-86. doi:10.1111/j.1471-4159.2006.03658.x. PMID: 16635254. View source.
4. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology. 2010;30(1):71-79. PMID: 19633950. View source.
5. Shevchenko KV, Nagaev IY, Andreeva LA, Shevchenko VP, Myasoedov NF. Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Russian Journal of Bioorganic Chemistry. 2006;32(1):57-62. PMID: 16523722. View source.
6. Dolotov OV, Zolotarev YA, Dorokhova EM, Andreeva LA, Alfeeva LY, Grivennikov IA, Myasoedov NF. The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation. Russian Journal of Bioorganic Chemistry. 2004;30(3):241-246. doi:10.1023/b:rubi.0000030127.46845.f0. PMID: 15344653. View source.
7. International Council for Harmonisation. Quality Guidelines: ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development. View source.
8. U.S. Food and Drug Administration. Questions and Answers on Current Good Manufacturing Practice Requirements—Records and Reports. View source.

Research Use Only Disclaimer

Research Use Only: The Adamax material supplied by NEXALUME LABS is sold solely as a laboratory research reagent and is not approved by the relevant regulatory authorities as a human or veterinary drug product.

This article provides general scientific information regarding standard laboratory research contexts only, and does not constitute a validated experimental protocol, medical guidance, clinical guidance, veterinary guidance, or treatment advice.